Clinical Trial

A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants

Study acronym: CRISTALSEA
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-07-01 -> 2027-03-27 2026-07-29
minor Completion pushed: 2026-07-01 -> 2027-03-27 2026-07-29
notable Trial sites expanded: 1 -> 6 locations 2026-06-19
Trial Details
NCT Number NCT07532863
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2
Enrollment 400 participants
Start Date 2026-03-13
Primary Completion 2027-03-27 (estimated)
Study Completion 2027-03-27 (estimated)
Updated on ClinicalTrials.gov 2026-07-28